![Scott Young](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Scott A. Young worked as Head-Investor Relations at Invivyd, Inc. from 2023 to 2024.
Mr. Young served as VP-Investor Relations & Corporate Communications at Xilio Therapeutics, Inc. Mr. Young was VP-Corporate Communications & Investor Relations at Flexion Therapeutics, Inc. from 2018 to 2022.
Anciens postes connus de Scott Young
| Sociétés | Poste | Fin |
|---|---|---|
| INVIVYD, INC. | Investor Relations Contact | 01/06/2024 |
| FLEXION THERAPEUTICS, INC. | Investor Relations Contact | 01/02/2022 |
| XILIO THERAPEUTICS, INC. | Investor Relations Contact | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
20
Relations au 1er degré
3
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Flexion Therapeutics, Inc.
 Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that discovers, develops and commercializes therapies for the treatment of patients with musculoskeletal conditions | Health Technology |
Xilio Therapeutics, Inc.
 Xilio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops tumor-selective immuno-oncology therapies | Health Technology |
Invivyd, Inc.
 Invivyd, Inc. BiotechnologyHealth Technology Develops antibody-based solutions for infectious diseases | Health Technology |
